Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

CNS tumours

2763 - Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): a metanalysis of randomized clinical trials (RCTs)


08 Oct 2016


CNS tumours


Giuseppe Lombardi


Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367


G. Lombardi1, L. Bellu2, A. Pambuku2, V. Zagonel2

Author affiliations

  • 1 U.o.c. Oncologia Medica 1, Veneto Institute of Oncology- IRCCS, 35128 - Padova/IT
  • 2 U.o.c. Oncologia Medica 1, Veneto Institute of Oncology- IRCCS, Padova/IT


Abstract 2763


GBMs are highly vascularized tumors and various ADs have been investigated in clinical trials showing unclear results. We performed this metanalysis to evaluate the effectiveness of ADs, in terms of progression-free survival (PFS) and overall survival (OS), as first or second-line therapy and their association with chemotherapy in GBM PTS.


The authors searched relevant published and unpublished RCTs analyzing ADs versus chemotherapy in GBM PTS from 2000 to January 2016 in MEDLINE, WEB of SCIENCE, ASCO, ESMO and SNO databases.


Sixteen RCTs (9 with bevacizumab, 2 cilengitide, 1 enzastaurin, 1 dasatinib, 1 vandetanib, 1 temsirolimus, 1 cediranib) were identified including 4566 PTS. All trials showed no improvement in OS with a pooled HR of 1.02 (95% CI 0.93-1.1; p = 0.7). The use of bevacizumab (BEV) did not improve OS; indeed, the pooled HR for OS for BEV studies (9 studies, 2752 PTS) was 0.98 (95% CI 0.89-1.08; p = 0.7); 6 RCTs (2084 PTS) analyzed BEV as first-line and the pooled HR for OS was 1.02 (95% CI 0.88-1.19; p = 0.8); 3 RCTs studied BEV as second-line therapy and the pooled HR for OS was 0.95 (95% CI 0.77-1.17; p = 0.6). No improvement of OS was shown when BEV was associated with chemotherapy (2588 PTS) with a pooled HR of 0.99 (95% CI 0.88-1.11; p = 0.8). Seven RCTs with a different AD demonstrating no improvement of OS versus standard treatment with a pooled HR of 1.05 (95% CI 0.89-1.23; p = 0.5). 14 RCTs (4349 PTS) were analyzed for PFS and the use of ADs showed a statistically longer PFS with a pooled HR of 0.73 (95% CI 0.62-0.86;p 


ADs did not improve OS in GBM PTS, both as first or second-line treatment. Among ADs, only BEV demonstrated a PFS benefit both as single agent or in combination with chemotherapy, both as first or second-line treatment.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings